Background: Hypertrophic pachymeningitis is an uncommon disorder that causes a localized or diffuse thickening of the dura mater and has been associated with rheumatoid arthritis, syphilis, Wegener's granulomatosis, tuberculosis, and cancer. Few series of the idiopathic variety have been described, particularly with respect to MRI correlation to clinical outcome and treatment. Objective: To investigate the clinical and laboratory evaluation, course, and treatment of patients with idiopathic hypertrophic pachymeningitis (IHP), to correlate the MRI findings with the clinical course, and to review the literature on IHP. Methods: Retrospective case series of 12 patients (9 men, 3 women), with a mean age of 55 years (range 39 to 88 years), who had IHP by imaging studies, meningeal or orbital biopsy, or both. The clinical features, laboratory evaluation, contrast-enhanced MRI, treatment, and clinical outcome were documented for each case. The mean duration of follow-up was 3.5 years (range 3 months to 16 years). Results: The main clinical features at presentation were headache (11 cases), loss of vision (7 cases), diplopia (4 cases), papilledema (2 cases), other cranial nerve involvement (3 cases), ataxia (2 cases), and seizures (1 case). On the initial MRI, the location of abnormal enhancement of the dura mater correlated with the clinical findings and the sphenoid wing area was affected in all patients. The sedimentation rate was elevated in five cases. The CSF had increased protein in six cases and lymphocytosis in four cases. Biopsy of the dura mater in five cases and the orbital soft tissue in one case showed infiltrates of small mature lymphocytes, plasma cells, and epithelioid histiocytes, but no neoplasia, vasculitis, or infectious agents. Cultures of the CSF and biopsy material remained sterile. Corticosteroid therapy improved the vision in 7 of 8 cases and controlled headache in 10 of 11 cases. Five cases had partial improvement of other neurologic symptoms and signs. Recurrence developed with steroid tapering in six cases. One case had progressive deterioration and died. In four cases methotrexate or azathioprine was added with reduction of the steroid dose. Follow-up MRI performed in 11 patients correlated 80% with the clinical state (p ϭ 0.01). Conclusion: IHP can be suspected on MRI and defined pathologically on biopsy. Untreated, the clinical course is usually marked by severe headache and progressive neurologic deterioration and vision loss. Although initially steroid-responsive, clinical manifestations frequently recur with corticosteroid taper, requiring the addition of immunosuppressive agents in some cases.
Hypertrophic pachymeningitis is a clinical disorder due to localized or diffuse thickening of the dura mater, with or without an associated inflammation. First described by Charcot and Joffroy as a "process in which the neighboring leptomeninges always suffers as well becoming opaque and thick, and further united to the dura and cord," 1 hypertrophic pachymeningitis of the spinal and later of the intracranial dura mater was described initially in association with trauma, infection, and tumors, 2 and more recently in association with Wegener disease. 3, 4 When the evaluation fails to reveal a cause, idiopathic hypertrophic pachymeningitis (IHP) is considered. IHP predominantly affects men and at the onset most of the patients have chronic headache, associated with or without neurologic manifestations such as cranial nerve palsies, cerebellar ataxia, and neuro-ophthalmic complications that include papilledema, optic neuropathy, visual field loss, and even blindness. [5] [6] [7] We evaluated the clinical and laboratory evaluation, course, and treatment of 12 patients with IHP. We reviewed the relevant literature on IHP and disorders that can have similar clinical or radiologic features.
Methods. We examined the records of patients evaluated by a referral neuro-ophthalmology or rheumatology service and excluded patients who had an etiology for the hypertrophic pachymeningitis (table 1). All patients had thickening and abnormal enhancement of the dura mater (without involvement of the pia/ arachnoid) demonstrated on gadolinium MRI T1 sequences performed prior to lumbar puncture. No patient had a history or clinical signs or symptoms of systemic collagen vascular disease, syphilis, Lyme disease, tuberculosis, or obvious metastatic cancer in the cranial bones adjacent to the abnormal dura mater. All patients had negative serum Venereal Disease Research Laboratory test (VDRL) and fluorescent treponemal antibody absorption (FTA-abs). The CSF protein, glucose, and cell count analyses were performed in 11 cases (Case 12 was originally misdiagnosed as meningioma so no CSF was obtained). The CSF analyses for VDRL, Lyme titer, cultures, and cytology for carcinomatous cells were negative. In 4 cases sputum and in 11 cases CSF were negative by stains and cultures for acid fast bacillus. Meningeal and orbital biopsies were negative for infectious agents by stains and cultures.
Additional serum serologic studies including antinuclear antibodies, rheumatoid factor, P and C-antineutrophil cytoplasmic antibody (ANCA), serum or immune electrophoresis or both, and angiotensin converting enzyme were performed in all cases. A chest x-ray was normal in all cases. A purified protein derivative was negative in all but one case who had received bacille Calmette-Guerin vaccination years before in Bulgaria.
The clinical symptoms and findings and MRI results at presentation and at multiple follow-up evaluations as well as the treatments were documented. The clinical neurologic status was classified as improved, worse, or stable (compared to the immediately prior examination) at the time when most follow-up MRI were performed. All MRI were evaluated by one neuroradiologist who was masked to the clinical status and treatments. The location and pattern of dura mater enhancement, described as linear, nodular, or both, 8 were analyzed for each MRI. Cranial CT was used primarily to assess bone and paranasal sinus involvement.
Follow-up gadolinium MRI were performed as clinically indicated, and the neuroradiologist assessed the findings as improved, worse, or no change in relation to the immediately prior MRI. On the final study, the degree of abnormal enhancement was defined as stable when unchanged, improved when there was less extensive enhancement or reduced thickness of the dura mater, and worse if there was increased enhancement compared to the initial study.
Results. Baseline features. Demographics. There were nine men and three women with a mean age of 55 years (range 36 to 88). Each patient was followed for an average of 3.5 years (range 3 months to 16 years) including one patient, Case 9, lost to follow-up after 3 months, and one patient, Case 8, who died after 3 months.
Clinical presentation features. At presentation, headache was the most common symptom, occurring in approximately 92% of patients (table 2) . The pain was severe in 10 of the 11 patients. Vision loss in one or both eyes due to optic neuropathy was the next most frequent presenting problem, occurring in 7 of 12 (58%) patients. The visual acuity loss ranged from 20/30 to complete blindness. Four patients had ophthalmoparesis due to third, fourth, or sixth cranial nerve involvement. Three patients had CNS dysfunction, two with gait ataxia (one with severe action tremor of the upper extremities) and one with seizures. Two patients had papilledema without visual loss, one with raised intracranial pressure (32 cm H 2 0) and one with spinal fluid protein of 243 mg/L. Laboratory evaluation and systemic disease. The serologies were negative except for Case 10 who had a positive c-ANCA without other features to suggest Wegener granulomatosis. The erythrocyte sedimentation rate was elevated (range 53 to 118 mm/hour) in five patients. The opening pressure on lumbar puncture was raised in two cases (Cases 3, 11). The CSF glucose was normal in all cases, and the protein was elevated, from 64 to 243 mg/L, in six patients. There was an increase in the number (range 12 to 100 mm 3 ) of CSF white blood cells, predominantly lymphocytes, in four cases. All cultures and stains for bacteria, tuberculosis, and fungi were negative.
Tuberculosis was suspected but was not confirmed by inspection and culture of sputum and CSF in Cases 1 and 2. Cranial CT in Case 4 with prostate carcinoma suggested metastatic disease but not adjacent to the affected dura. Case 10 developed breast carcinoma 8 years after presentation. Case 5 developed metastatic thyroid papillary carcinoma 3 years after improved cranial nerve function and partial resolution of the IHP on MRI.
Neuroimaging. By definition, abnormal dural enhancement was detected on the initial gadolinium enhanced MRI in all patients. The enhancement pattern was nodular in two (figure 1A), linear in three, and a combination of linear and nodular in seven MRI. Nine patients had falx cerebri and tentorium cerebelli involvement, with a linear pattern in six (figure 2). Nodular involvement of the falx cerebri was present in one, that showed a linear pattern on follow-up MRI, and both types of pattern occurred in two MRI. Cavernous sinus involvement appeared nodular and was appreciated in six MRI. All 12 patients had enhancement of the dura mater of the sphenoid wing Histopathology. Meningeal biopsies, performed in five patients (Cases 1, 3, 8, 10, and 12), and orbital soft tissue biopsy in one patient (Case 6) showed infiltrates of small mature lymphocytes, plasma cells, and epithelioid histiocytes, two with granuloma (Cases 1 and 12), but none had signs of vasculitis or neoplastic cells or infectious agents.
Course and therapy. Worsening before treatment. When untreated for several months, progressive disease was documented in six patients. New involvement of the cranial nerves XI and XII, and worse hearing loss from the right ear, right facial weakness, and hypopituitarism requiring estrogen, cortisone, thyroid replacement, and desmopressin acetate (Case 10) developed. Worse vision occurred in both eyes and worse ataxia occurred in Case 4. New visual loss and a right hemiparesis developed in Case 2. The vision in the affected eye worsened in three patients (Cases 1, 3, and 6).
During the course of the disease the optic nerve was the cranial nerve most frequently affected (11 eyes in eight patients) but the sixth nerve was commonly involved (four patients) as well. Other cranial nerves were involved with a lesser frequency, but cranial nerves nine and ten were not affected (see table 2 ). No patient reported the loss of smell or taste.
Response to therapies. Ten patients had improvement in headache, neurologic dysfunction, or both after initiating high dose oral corticosteroid treatment (60 to 80 mg per day) (table 3) . Worsening of existing disorders or new neurologic dysfunction commonly occurred with prednisone dose reduction and resolved with raising the dose.
Due to the need for continued large doses of prednisone, three patients were treated with methotrexate (Cases 3, 6, and 10) and one patient was treated with azathioprine (Case 11). Due to gastrointestinal adverse effects of methotrexate, Case 6 was later switched to azathioprine 200 mg daily and remained on 7.5 mg of prednisone as well. Also, Case 11 had an optic neuropathy in a previously unaffected eye after 2 years of azathioprine 250 mg and prednisone 10 mg daily. The vision recovered after IV methylprednisolone, and he was switched to methotrexate, 15 mg per week, and oral prednisone with gradual reduction to 10 mg daily.
Clinical and MRI outcome. There was one death (Case 8 after 3 months) related to the pachymeningitis and one death 1 year after diagnosis (Case 4) due to metastatic cancer. One patient (Case 9) was lost to follow-up having resolved the sixth nerve paresis and headache after approximately 2 months of prednisone. Of the nine patients still followed (mean 4.6 years), three patients have received no therapy for more than 1 year, two of whom (Cases 2 and 7) are asymptomatic. The third (Case 1) had recurrent headaches within 1 year of stopping prednisone without a change in the MRI. Three patients remained stable on methotrexate (10 to 20 mg weekly) or azathioprine (250 mg daily) and 5 to 7.5 mg of daily prednisone (Cases 3, 6, and 11). A fourth patient (Case 10) received 22.5 mg methotrexate per week and 15 mg per day of prednisone. One year before Case 10 developed breast cancer, a consultant from another institution switched Case 10 from cyclophosphamide 125 mg to 175 mg daily despite control of clinical symptoms because he thought there was worsening of the MRI, although we did not. One patient (Case 12), who originally improved on steroids with cessation of seizures, has recently had recurrence of headache and short-term memory difficulties, 9 months after stopping steroids. These symptoms persist despite prednisone 10 mg daily after a 6-week dose reduction starting at 30 mg.
Follow-up MRI evaluation was performed in 11 patients (average of four MRI), with the longest radiographic follow-up performed at 16 years following initial study. The MRI was worse 13 times with clinical worsening, once with an unchanged clinical status, and never with clinical improvement (figures 1C and 3C). The MRI was improved seven times with clinical status improvement, three times with unchanged clinical status, and never with clinical worsening (figure 3, B and D). The MRI was unchanged 15 times with unchanged clinical status, three times with clinical improvement, and once with clinical worsening. In the six patients who did not have biopsies, the MRI im- proved in five and remained stable in one. Follow-up MRI and clinical state correlated 80% of the time (p ϭ 0.01).
The final MRI was worse in three patients, including Case 8, who failed to improve on follow-up MRI despite high dose daily steroids; Case 11, who was on prednisone and methotrexate but only had orbital inflammation on the first MRI; and Case 12, who initially improved after high dose steroids. Despite retreatment with prednisone 30 mg daily with reduction to 10 mg daily over 6 weeks, one patient (Case 12) had worse temporal lobe edema and increased nodular enhancement in the adjacent dura matter in addition to short-term memory loss (figure 1, C and D). The final MRI (performed at 1 to 16 years) was improved in four patients, including Case 1 after 9 months of prednisone, Case 5 on replacement steroid only for years, Case 6 on low dose prednisone and azathioprine, and Case 7 after being withdrawn from prednisone for more than 6 months. Final MRI stability (performed at 1 to 6 years) was appreciated in four patients, including Case 4, who had worse vision without change in the MRI prior to treatment, Case 2 after treatment with prednisone, and in two patients (Cases 3 and 10) during treatment with prednisone and methotrexate.
Discussion. In our case series of 12 patients with IHP diagnosed by MRI, laboratory studies, and in some cases biopsy, the inflammation of the dura mater caused headache in all but one case and frequently caused visual loss and lid and ocular motor dysfunction due to involvement of the dura surrounding the intracranial optic nerve and the cavernous sinus. Less often the dural inflammation caused signs of increased intracranial pressure, including papilledema or a wide based gait, possibly from blockage of CSF outflow through the arachnoid granulations or due to compromise of the dural venous sinuses, 7, 9, 10 although we made no specific effort to document the latter mechanism. CNS parenchymal dysfunction that caused tremor and gait imbalance, hemiparesis, memory loss, or seizures was less common. When the dura mater at the skull base in the posterior fossa was affected, neuropathy of the lower cranial nerves occurred. The clinical features appeared to be associated with the location of the abnormal dura observed on gadolinium MRI. Although studies on IHP have described the seventh nerve followed by the lower cranial nerves as the most frequently affected, 5,10 others have described preferential dysfunction in the cranial nerves that serve ocular motor function particularly with parasellar involvement. 8 Due to the nature of the referrals to a neuro-ophthalmology service, the most prevalent neurologic problems, visual loss and ocular motor dysfunction, might merely reflect a referral bias.
Due to the extensive differential diagnosis (see table 1), the evaluation of IHP requires blood and CSF evaluation, contrast MRI, a general physical examination, and on occasion, biopsy of the dura mater or orbital tissue. Serum angiotensin converting enzyme, c and p-ANCA, rheumatoid factor, and antinuclear antibody are typically not elevated. As occurred in 41% of our patients, the erythrocyte sedimentation rate can be elevated. 11 Evaluation for Lyme, syphilis, tuberculosis, and fungi should be negative. Lumbar puncture with CSF analysis for infection and neoplasia are negative. On occasion with IHP, the opening pressure is elevated. The chemistry of CSF is variable and nondiagnostic, but the protein can be elevated as occurred in 50% of our cases. CSF lymphocytosis is variably present. Although we had biopsies suggestive of IHP in only six patients, the six patients with presumed IHP who were not biopsied were followed from 1 to 3 years and did not develop signs of infection or other causes for the pachymeningitis. Cranial gadolinium MRI is more sensitive than contrast enhanced CT in demonstrating the thickened abnormally enhancing dura mater. Enhancement of the arachnoid membrane should be absent. A noncontrast CT should exclude neoplasia, usually metastases, in the bone adjacent to the affected dura mater, although the biopsy of the abnormal dura mater in these cases has revealed inflammation rather than tumor infiltration. 12 Other neoplasia and intracranial hypotension may have similar MRI appearance. [13] [14] [15] [16] In IHP the gadolinium-enhanced MRI used to evaluate the localization, extent, and pattern of abnormal dura and to monitor disease progression as the abnormal areas appear to correlate with the pathologic inflammatory process. Prior authors described various patterns of dural enhancement with tentorium and falx and extension in the adjacent dura as most common (75% of our cases), with cavernous sinus involvement next most frequent. 10 The frequency of abnormal enhancement of the sphenoid wing dura mater (100%) and the cavernous sinus (50%) in our series might reflect a bias to patients with neuro-ophthalmologic symptoms. The skull base, basilar cisterns, orbits, paranasal sinuses, and sella turcica were involved less often in our series. Dural involvement can be linear or nodular, and both patterns can be seen in the same patient, with the pattern usually depending on the specific segment of affected dura mater. Our series also shows the localization of abnormal dural enhancement may aid the clinician in delineating all the clinical features. For example, involvement of the sella turcica and dura around the optic nerves and cavernous sinus correlated with the visual loss, cranial neuropathy, as well as the pituitary dysfunction in the two patients.
Venous sinus thrombosis and cerebral edema can complicate this disease process. 10, 17, 18 Except for the one patient with seizures who had edema in the temporal lobe adjacent to the affected dura, no patient in our series had an obvious associated brain lesion. Dural venous sinus obstruction was not appreciated in our patients. As previously noted, there is little correlation between the CSF cellular response and the extent of abnormal dura mater on MRI, 19 how- Memory loss Prednisone ever, in our cases, patients with abnormal protein tended to have more diffuse dural involvement. Prior efforts to correlate MRI changes with the clinical course have been limited by short follow-ups and in one report only two of the five patients with IHP were followed for 2 years or longer. 20 The abnormal enhancement of the dura mater on MRI does not usually resolve. 7, 18 However, the MRI can be used to monitor the effect of therapy as judged by stabilization or reduction of the extent or thickness of the abnormal enhancement. In our case series, MRI frequently improved when the clinical assessment was improved and worsened when the patient was clinically worse. Except for two cases who had no demonstrable change in the MRI, of the 10 patients with follow-up MRI one year or longer, eight demonstrated MRI improvement at some point during their treatment.
Biopsy of the dural lesion should be considered and is recommended if the patient clinically deteriorates or the neuroimaging worsens despite treatment. Although this procedure carries a low risk, one of our patients had a symptomatic subdural hematoma that required emergency evacuation. Chronic inflammation of the usually inert dura mater with minimal or no inflammation of pia and arachnoid should be seen in IHP. Lymphocytes, plasma cells, macrophages, epithelioid cells, and occasionally granulomas infiltrate the dura, later to be replaced by fibrosis. Rarely, vasculitis is demonstrated as well. 21 Similar to orbital pseudotumor, areas of active inflammation respond to therapy whereas the fibrotic component may be less responsive to therapy.
Hypertrophic pachymeningitis, from all causes, can affect the spinal as well as the cranial dura mater. The spinal pachymeningitis usually involves the cervical and high thoracic regions of the spinal cord. 22 IHP rarely affects the spine and the lower brainstem skull base with lower cranial neuropathy. 23 Inflammation of the orbital dura due to orbital pseudotumor with intracranial extension, on occasion with bone erosion, has also been described. 24 Astrom and Lidholm described a case of granulomatous inflammation of the orbit that spread intracranially with significant sinus inflammation that, although attributed to systemic periarteritis nodosum, may have been due to Wegener granulomatosis. 25 The patient had granulomatous involvement of the subarachnoid space and pia not typical of IHP, developed renal failure, pericardial inflammation, and dementia, and died. The autopsy revealed vasculitis with associated chronic and acute granulomatous inflammation in the affected tissues, also not characteristic of IHP. Rogers and Roberto reported a patient who had unilateral superior orbital fissure involvement with complete unilateral ophthalmoplegia and subsequent cavitary lung lesions, hematuria, and death. 26 The biopsy and postmortem histology of the dura mater showed "marked fibrosis and inflammation, including signs of acute vasculitis." Painful ophthalmoplegia due to localized inflammation of the superior orbital fissure or anterior cavernous sinus dura 27, 28 can be difficult to demonstrate without using high resolution coronal views on contrast CT or fat suppressed MRI. Less frequently, the inflammatory process can extend from the orbit to involve the dura mater over the frontal lobes and multiple cranial nerves. 29 Although pachymeningitis is uncommon in patients with typical clinical and radiographic features of orbital pseudotumor, intracranial extension can occur with or without vasculitis or signs of systemic disease.
Infrequently, hypertrophic pachymeningitis may be related to other fibrosclerotic diseases such as sclerosing cholangitis, episcleritis, Riedel thyroiditis, testicular fibrosis, mediastinal fibrosis, and subcutaneous fibrosis, 30 or episcleritis, orbital pseudotumor, and sclerosing cholangitis. 31 Other extracranial manifestations include pulmonary nodules with the same pathology as in the affected dura mater, 32 granulomatous skin infiltration, 5 and myocarditis. 33 Systemic autoimmune and rheumatologic diseases that can present with similar clinical and radiologic features must be considered in the evaluation of IHP. 34, 35 Seldom, patients with rheumatoid arthritis develop headache and optic neuropathy with fibrosis and chronic inflammatory infiltrate of the dura mater without giant cells or rheumatoid nodules. [36] [37] [38] [39] Temporal arteritis, without giant cells, with inflammation and multifocal abnormal enhancement of the dura mater rarely occurs. 40 Wegener granulomatosis has also been associated with hypertrophic pachymeningitis. 3, 4, 9, 19, 41, 42 In most cases sinus or systemic disease affecting the kidneys or lungs is present. 3, 4, 43 A combination of corticosteroid and cyclophosphamide treatment controls the pachymeningitis. Although negative serologies and nonspecific chronic inflammation without vasculitis in the dura mater biopsy are suggestive of IHP, as in Case 10 who had a positive c-ANCA, it is the clinical profile that excludes Wegener's. Biopsy of the dura mater revealed only nonspecific inflammation without necrotizing granulomas or vasculitis and no other clinical systemic inflammatory manifestations developed over an 8-year interval. Although a positive p-ANCA is common in Wegener granulomatosis, a positive c-ANCA, as in Case 10, is rare with pachymeningitis from any etiology.
Several authors reported the association of end stage kidney disease of unknown cause with development of hypertrophic pachymeningitis. 11, 44 It is unclear if the pachymeningitis was related to the underlying cause of renal failure or was a complication of the dialysis process. One such patient with renal failure of unknown etiology developed vocal cord, sternocleidomastoid, and tongue weakness as well as reduced hearing, followed by progressive severe visual loss due to optic neuropathy 2 years after hemodialysis was begun. The patient died of a spontaneous intracerebral hemorrhage and the autopsy revealed granulomatous thickening of the dura mater with necrosis, but no evidence of primary vasculitis. 44 IHP frequently progresses if untreated and although corticosteroid treatment improves the majority of patients, the benefit may be temporary and partial. Masson et al. 7 described seven cases of IHP whose symptoms improved with corticosteroid therapy and reappeared after dose reduction or stopping. The dural thickening persisted despite clinical improvement. One case was treated with azathioprine, allowing a reduction in the steroid dose. Improvement or stabilization in optic neuropathy has been reported with repeated corticosteroid therapy over a 1-year interval. 17 In our series with longer follow-up, the majority of patients with visual loss improved rapidly and maintained their vision on therapy, suggesting the visual loss was secondary to inflammation rather than due to compressive fibrosis around the optic nerve. Similarly, the gait imbalance, hemiparesis, and epilepsy improved with corticosteroid treatment but we cannot exclude that some improvement occurred because of better CSF absorption. Our results as well as other studies show that azathioprine or methotrexate can allow tapering of the steroids. Hamilton et al. reported three patients, followed from 2 to 7 years, with optic neuropathy or painful ophthalmoparesis or both where the symptoms in two cases were controlled only by high dose prednisone, until azathioprine (dose not specified) was added. 11 In the third case there was no improvement with methotrexate, but the clinical symptoms resolved with chloroquine therapy and 4500 cGy of whole-brain radiation. However, in most reports, radiotherapy does not appear to be an effective therapy for IHP. 7 The abnormal dural enhancement on MRI can persist despite a good clinical response to corticosteroids or other immunosuppressive agents or both. However, reduced enhancement and thickness of the affected dura mater seen after treatment, mostly in our patients who clinically improved, contrasts with Masson et al.'s report of no change. 7 This difference may suggest that more of our cases had not evolved to the fibrotic stage prior to treatment.
To our knowledge, this is the first study to use MRI to follow a series of patients with IHP. The gold standard for the diagnosis is biopsy of the thickened dura mater, which typically shows chronic inflammatory infiltrate with lymphocytes, palisading histiocytes, and variable amounts of fibrosis and remains culture negative. Without treatment, progressive neurologic deterioration, especially vision loss, can occur. If clinical manifestations recur with steroid taper, methotrexate or azathioprine may help control the pathologic process and reduce the amount of daily steroids needed.
